

APPLICANTS: Wands et al.

FILED: Herewith

In the claims:

Cancel claims 1-15, 23-36 and 38.

Add new claims 39-56.

- A 2
39. The method of claim 16, wherein said compound is an antibody or fragment thereof which binds to HAAH.
 40. The method of claim 39, wherein said antibody or fragment thereof binds to an epitope in the catalytic domain of HAAH.
 41. The method of claim 16, wherein said compound is a single chain Fv molecule.
 42. The method of claim 16, wherein said compound is a FB50 antibody.
 43. The method of claim 16, wherein said compound is a FB50 single chain Fv molecule.
 44. The method of claim 19, wherein said mutation comprises a substitution or deletion of a histidine residue in said catalytic domain of HAAH.
 45. The method of claim 19, wherein said mutation is located between residues 650-700 of SEQ ID NO:2.
 46. The method of claim 19, wherein said mutation is a substitution or deletion at residue 675 of SEQ ID NO:2.
 47. The method of claim 19, wherein said mutation is a substitution or deletion at residue 679 of SEQ ID NO:2.
 48. The method of claim 19, wherein said mutation is a substitution or deletion at residue 690 of SEQ ID NO:2.
 49. The method of claim 19, wherein said compound is administered directly into a tumor site.
 50. The method of claim 19, wherein said compound is administered systemically.
 51. The method of claim 16, wherein said tumor is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.
 52. The method of claim 16, wherein said tumor is a cancer of the central nervous system.
 53. The method of claim 16, wherein said tumor is a hepatocellular carcinoma.
 54. The method of claim 16, wherein said tumor is a cholangiocarcinoma.
 55. The method of claim 16, wherein said tumor is a glioblastoma.
 56. The method of claim 16, wherein said tumor is a neuroblastoma.